A Multicentre, Double-Blind, Double-Dummy, Two-Phase Crossover Study of Nasalfent (Fentanyl Citrate Nasal Spray) Compared to Immediate Release Morphine Sulphate Tablets in the Treatment of Breakthrough Cancer Pain (BTCP) in Subjects Taking Regular Opioid Therapy.
Phase of Trial: Phase III
Latest Information Update: 21 Jun 2012
At a glance
- Drugs Fentanyl; Morphine
- Indications Cancer pain
- Focus Registrational; Therapeutic Use
- 21 Jun 2012 Primary endpoint identified as (Assessment scale scores) as reported by European Clinical Trials Database record.
- 21 Jun 2012 Planned number of patients changed from 80 to 200 as reported by European Clinical Trials Database record.
- 21 Jun 2012 Inclusion and exclusion criteria amended as reported by European Clinical Trials Database record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History